High materiality9/10
Summit Therapeutics price target lowered to $38 from $40 at Guggenheim
Why it may matterVerify against the original reporting
upside_potential
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim lowers Summit Therapeutics' price target to $38 from $40; current price around $14.98; implied upside ≈ 154%.
- Guggenheim lowers SMMT target to $38 from $40; price ≈ $14.98; upside ≈ 154%
Key facts
- 01
Target: $38
- 02
Posted price: $14.98
- 03
Analyst firm: Guggenheim
- 04
Analyst: Brad Canino
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.